The Six Food Elimination in Postprandial Distress Syndrome
Universitaire Ziekenhuizen KU Leuven
15 participants
Feb 19, 2020
INTERVENTIONAL
Conditions
Summary
The six food elimination diet, as known in eosinophilic esophagitis, will be performed in 15 patients with functional dyspepsia (subtype postprandial distress syndrome). Screening will exclude patients with allergies by performing immunocaps on blood. Before and after the 8 weeks of diet, an gastroduodenoscopy with biopsies will be performed to evaluate duodenal eosinophilia, mast cells and permeability. To evaluate gastric sensorimotor function, a gastric emptying breath test and a barostat test will be performed before and after the diet. Symptoms will be monitored with a daily diary (LPDS diary) and food intake will be evaluated during 2 weeks. If there is an improvement of symptoms during the diet, a reintroduction period will start. This period will last 6 weeks. Every 2 weeks, two food groups will be reintroduced. When there is a clear worsening in symptoms, a new endoscopy with biopsies will be performed.
Eligibility
Inclusion Criteria6
- Functional dyspepsia patients with meal related symptoms (Rome IV Postprandial Distress Syndrome, PDS)
- Witnessed written informed consent prior to any study procedures
- Patients aged between 18 and 70 years inclusive
- Male or female patients
- Women of child-bearing potential agree to apply a highly effective method of birth control during the entire duration of the trial. Women of non-childbearing potential may be included if surgically sterile or postmenopausal with at least 2 year without spontaneous menses.
- Subject is capable to understand the study and the questionnaires, and to comply with the study requirements.
Exclusion Criteria14
- History of gastrointestinal surgery (other than appendectomy).
- Organic gastro-intestinal disease
- Major psychiatric disorder
- Patients with eosinophilic esophagitis
- Presence of diabetes mellitus
- Presence of coeliac disease, lupus, scleroderma and other systemic auto-immune disease.
- Active H. Pylori infection or < 6 months after eradication
- Predominant irritable bowel syndrome (IBS)
- Predominant gastro-oesophageal reflux disease (GERD)
- Atopic constitution or food allergy
- Ongoing diet which interferes with the 6 food elimination diet.
- Drugs altering gastric emptying or anti-inflammatory drugs
- Females who are pregnant or lactating
- Patients not capable to understand or be compliant with the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
No blinded, no controlled intervention.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05651386